Y-mAbs Therapeutics, Inc. revenue breakdown overview

Y-mAbs Therapeutics, Inc. revenue for the last year amounted to 85.19 M USD, the most of which — 85.19 M USD — came from its highest performing source at the moment, Novel Antibody-based Therapeutic Products, the year earlier bringing 84.32 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Y-mAbs Therapeutics, Inc. 65.98 M USD, and the year before that — 67.81 M USD.